Keywords: cure, rate, mrsa, csssi, ceftobiprole, health, care
90% cure rate for MRSA cSSSI with J&J's ceftobiprole
Article | 01 October 2007
US health care major Johnson & Johnson's investigational antibiotic ceftobiprole was as effective as commonly-used combination therapy in treating patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
